[HTML][HTML] Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
SA Wells Jr, BG Robinson, RF Gagel… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
Journal of clinical oncology, 2012•ncbi.nlm.nih.gov
Purpose There is no effective therapy for patients with advanced medullary thyroid
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular
endothelial growth factor receptor, and epidermal growth factor receptor signaling, has
previously shown antitumor activity in a phase II study of patients with advanced hereditary
MTC.
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular
endothelial growth factor receptor, and epidermal growth factor receptor signaling, has
previously shown antitumor activity in a phase II study of patients with advanced hereditary
MTC.
Abstract
Purpose
There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.
ncbi.nlm.nih.gov